You are here

A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI112133-01
Agency Tracking Number: R41AI112133
Amount: $599,996.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-124
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-07-01
Award End Date (Contract End Date): 2016-06-30
Small Business Information
BOX 8175
New Haven, CT 06530-0175
United States
DUNS: 142406110
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (203) 737-2642
Business Contact
Phone: (203) 393-9439
Research Institution
NEW HAVEN, CT 06520-8327
United States

 Nonprofit College or University

DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these proteins individually provided partial impairment of spirochete transmission to the murine host Simultaneously targeting these proteins might compromise multiple steps of transmission and effectively thwart transmission Towards this new strategy to prevent Lyme disease we will assess the efficacy of vaccine targeting A A combination of Borrelia interacting tick proteins TRE and Salp to impair interactions that facilitate spirochete egress from the gut and interactions that ensure spirochete survival in the host respectively B A combination of Borrelia assisting salivary proteins Tick Salivary Lectin Pathway Inhibitor TSLPI and tick histamine release factor tHRF that do not physically associate with the spirochete but play a significant role in enhancing spirochete survival in the host during transmission and in tick engorgement respectively and C A combination of Borrelia interacting Salp and TRE and Borrelia assisting TSLPI and tHRF tick proteins to effectively thwart spirochete arrival and survival at the tick bite site Such a systematic approach has hitherto not been explored and could in principle also be applicable to thwart other arthropod borne pathogens The success of this multipronged derailment approach will provide the basis for the formulation of a multivalent tick antigenic peptide based vaccine against Lyme disease in Phase II efforts PUBLIC HEALTH RELEVANCE This proposal seeks to develop a safe and effective vaccine against Lyme disease by targeting tick salivary and gut proteins critical for the transmission o the Lyme disease agent from the tick to mammalian host

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government